Triple-negative breast cancer (TNBC), as an important subtype of breast cancer, has stronger invasion, higher recurrence and metastasis rates, shorter survival time and more refractory treatment than those of non-TNBC due to negativities of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.